Amebic liver abscess: An update

医学 肝脓肿 脓肿 甲硝唑 门静脉血栓形成 败血症 血栓形成 内科学 抗生素 外科 生物 微生物学
作者
Ramesh Kumar,R. S. Patel,Rajeev Nayan Priyadarshi,Ruchika Narayan,Tanmoy Maji,Utpal Anand,Jinit R Soni
出处
期刊:World Journal of Hepatology [Baishideng Publishing Group]
卷期号:16 (3): 316-330 被引量:16
标识
DOI:10.4254/wjh.v16.i3.316
摘要

Amebic liver abscess (ALA) is still a common problem in the tropical world, where it affects over three-quarters of patients with liver abscess. It is caused by an anaerobic protozoan Entamoeba hystolytica , which primarily colonises the cecum. It is a non-suppurative infection of the liver consisting primarily of dead hepatocytes and cellular debris. People of the male gender, during their reproductive years, are most prone to ALA, and this appears to be due to a poorly mounted immune response linked to serum testosterone levels. ALA is more common in the right lobe of the liver, is strongly associated with alcohol consumption, and can heal without the need for drainage. While majority of ALA patients have an uncomplicated course, a number of complications have been described, including rupture into abdomino-thoracic structures, biliary fistula, vascular thrombosis, bilio-vascular compression, and secondary bacterial infection. Based on clinico-radiological findings, a classification system for ALA has emerged recently, which can assist clinicians in making treatment decisions. Recent research has revealed the role of venous thrombosis-related ischemia in the severity of ALA. Recent years have seen the development and refinement of newer molecular diagnostic techniques that can greatly aid in overcoming the diagnostic challenge in endemic area where serology-based tests have limited accuracy. Metronidazole has been the drug of choice for ALA patients for many years. However, concerns over the resistance and adverse effects necessitate the creation of new, safe, and potent antiamebic medications. Although the indication of the drainage of uncomplicated ALA has become more clear, high-quality randomised trials are still necessary for robust conclusions. Percutaneous drainage appears to be a viable option for patients with ruptured ALA and diffuse peritonitis, for whom surgery represents a significant risk of mortality.With regard to all of the aforementioned issues, this article intends to present an updated review of ALA.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
风中星月完成签到 ,获得积分10
1秒前
老板多加香菜完成签到 ,获得积分10
3秒前
小成完成签到 ,获得积分10
6秒前
Orange的应助被菊花茶采纳,获得10
11秒前
彦成完成签到,获得积分10
12秒前
safari完成签到 ,获得积分10
14秒前
超帅傲白完成签到,获得积分10
18秒前
Monroe完成签到 ,获得积分10
21秒前
安安完成签到,获得积分10
22秒前
yyyyyz完成签到,获得积分10
23秒前
69岁扶锄种地完成签到 ,获得积分10
26秒前
32秒前
胖胖完成签到 ,获得积分0
34秒前
乐乐的应助被今天不看文献采纳,获得10
35秒前
nanting完成签到 ,获得积分10
37秒前
Della完成签到 ,获得积分10
37秒前
小梓完成签到 ,获得积分10
39秒前
43秒前
melody完成签到,获得积分10
44秒前
紧张的书文完成签到 ,获得积分10
44秒前
刘一安完成签到 ,获得积分10
45秒前
坦率的语芙完成签到,获得积分10
45秒前
choin6688_完成签到 ,获得积分10
46秒前
寒江孤影完成签到,获得积分10
48秒前
Ann发布了新的文献求助10
48秒前
48秒前
老猫322完成签到 ,获得积分10
50秒前
Xulyun完成签到 ,获得积分10
50秒前
友好的牛排完成签到,获得积分0
51秒前
万能图书馆的应助被科研通管家采纳,获得100
51秒前
赘婿的应助被科研通管家采纳,获得10
51秒前
酷炫的初阳完成签到,获得积分10
52秒前
尊敬的鱼完成签到,获得积分10
52秒前
FuFu完成签到 ,获得积分10
53秒前
丘比特的应助被王蕊采纳,获得10
55秒前
能干的草莓完成签到,获得积分10
57秒前
FAHUO完成签到,获得积分10
57秒前
大个的应助被六六采纳,获得10
57秒前
Ann完成签到,获得积分10
57秒前
光亮的小甜瓜完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Aspects of Post-SPE Phonology 2000
Nanocomposite Removal of Pesticides from Wastewater 1000
Practical Manual of Forensic Psychophysiology: Methodology, Execution, and Fields of Application 800
Rosenblum, Global Change Biology 800
Final Report for the 2-D Test of Model 901 Rotor and Wing Airfoils (BSWT 592) 528
Berberine regulates the TLR4 signaling pathway to suppress hypoxia-induced proliferation and migration of pulmonary arterial smooth muscle cells 520
热门求助领域 (近24小时)
化学 材料科学 医学 生物 计算机科学 工程类 纳米技术 有机化学 物理 生物化学 化学工程 内科学 复合材料 催化作用 心理学 人工智能 细胞生物学 光电子学 无机化学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 7909438
求助须知:如何正确求助?哪些是违规求助? 9412562
关于积分的说明 20899235
捐赠科研通 7510233
什么是DOI,文献DOI怎么找? 3362407
关于科研通互助平台的介绍 2500317
邀请新用户注册赠送积分活动 2392923